Overall, additional molecular and clinical outcome studies with larger numbers of carefully classified tumors will be essential to determine whether tumors with features of grade 3 NET are biologically distinct from NEC, or whether they should be considered along the spectrum of a heterogeneous group of LCNEC without p53/RB alterations. This evidence concerns the gene TP53 and large cell neuroendocrine carcinoma.